Abstract
Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT). Leukemia resistance and secondary graft-versus-host disease (GVHD) are major obstacles to success with DLI. The aim of this study was to identify pre-DLI factors associated with prolonged survival in remission without secondary GVHD. We retrospectively analyzed 500 patients treated with DLI for CML relapse (16% molecular, 30% cytogenetic, and 54% hematological) after alloSCT. The overall probabilities of failure- and secondary GVHD-free survival (FGFS) were 29% and 27% at 5 and 10 years after DLI, respectively. The type of relapse was the major factor influencing FGFS (40% for molecular and/or cytogenetic relapse and 20% for hematological relapse at 5 years, P < .001). Chronic GVHD before DLI and an interval <1 year between alloSCT and first DLI were independently associated with inferior FGFS in patients with molecular and/or cytogenetic relapse. Consequently, FGFS was 13%, 35%, to 56% at 5 years in patients with 2, 1, and 0 adverse features, respectively. In patients with hematological relapse, independent adverse prognostic factors for FGFS were initial dose of CD3(+) c...Continue Reading
References
Aug 28, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·D L PorterJ H Antin
May 3, 2002·Blood·Eduardo OlavarriaJohn M Goldman
Jul 2, 2002·Blood·Cesare GuglielmiDietger Niederwieser
Apr 15, 2003·Bone Marrow Transplantation·A M RaiolaA Bacigalupo
Sep 13, 2003·Leukemia·E OlavarriaUNKNOWN Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT)
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel J DeAngeloRobert J Soiffer
Oct 6, 2005·Bone Marrow Transplantation·B N SavaniA J Barrett
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georg HessThomas Fischer
Nov 25, 2006·Hematology·Jane F Apperley
Mar 16, 2007·Leukemia·M P SimulaF Dazzi
Apr 24, 2007·Best Practice & Research. Clinical Haematology·F Dazzi, C Fozza
Jul 28, 2009·Bone Marrow Transplantation·Y ChalandonUNKNOWN Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation
Dec 5, 2009·Best Practice & Research. Clinical Haematology·Alois Gratwohl, Dominik Heim
Apr 13, 2010·Cancer Treatment Reviews·Abhinav Deol, Lawrence G Lum
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Mar 26, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Merav BarMary E D Flowers
Jun 28, 2013·Blood·Michele BaccaraniRüdiger Hehlmann
Jul 5, 2013·PloS One·Hua JinQifa Liu
Citations
Dec 8, 2017·Journal of Internal Medicine·C CraddockUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK
Dec 18, 2015·Biomarker Insights·E V MorozovaB V Afanasyev
Dec 10, 2017·Hematology·Melanie Grant, Catherine M Bollard
Apr 25, 2019·Leukemia & Lymphoma·Evandro D BezerraCelestia S Higano
Jan 4, 2018·Blood Advances·Melanie Grant, Catherine M Bollard
Jun 24, 2017·Frontiers in Immunology·Anne M DickinsonHans Jochem-Kolb
May 29, 2019·The Cancer Journal·Premal D LullaMalcolm K Brenner
Jan 10, 2017·The Journal of Clinical Investigation·Cornelis A M van BergenJ H Frederik Falkenburg
Jul 29, 2020·Cytotherapy·Bechara MfarrejClaude Lemarie
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph SchmidGesine Bug
Feb 18, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sarah SchmidtWael Saber
Dec 26, 2018·Bulletin du cancer·John De VosThierry Guillaume
Dec 5, 2017·Blood Reviews·Melanie L Grant, Catherine M Bollard
Dec 4, 2020·Blood·Premal D LullaAnn M Leen